Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation
This article was originally published in The Pink Sheet Daily
Executive Summary
Anticipated reorganization seems to mimic previous actions by Big Pharma, with an emphasis on external collaboration and a move to smaller, independent groups..
You may also be interested in...
Zerhouni Moves Up At Sanofi-Aventis To President Of Global R&D
Former NIH director drafted by Viehbacher in early 2009 to be his science advisor replaces Cluzel as R&D chief.
Zerhouni Moves Up At Sanofi-Aventis To President Of Global R&D
Former NIH director drafted by Viehbacher in early 2009 to be his science advisor replaces Cluzel as R&D chief.
Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?
Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.